InnoCare Pharma (HKG:9969) said Australia's Therapeutic Goods Administration approved orelabrutinib for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, according to a Wednesday Hong Kong bourse filing.
Shares of the pharmaceutical company fell by over 2% in late-morning trade on Thursday.